Mercator MedSystems
  • Home
  • Corporate Mission Officers and Directors
  • Bullfrog Micro-Infusion Device Blowfish Transbronchial Micro-Infusion Device
  • Peripheral Artery Disease Bronchial Carcinoma Peer-Reviewed Publications
  • TANGO LIMBO DANCE BROADWAY Other Trials
  • Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris MedTech Strategist Nov 27, 2017 Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINC Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study Late-Breaking Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at VIVA 2016 LIMBO-ATX Trial Begins in United States LIMBO-PTA Trial Begins in Germany Trent Reutiman Named CEO Archives
  • Contact
Mercator MedSystems
  • Home/
  • About Us/
    • Corporate Mission
    • Officers and Directors
  • Products/
    • Bullfrog Micro-Infusion Device
    • Blowfish Transbronchial Micro-Infusion Device
  • Science and Technology/
    • Peripheral Artery Disease
    • Bronchial Carcinoma
    • Peer-Reviewed Publications
  • Clinical Trials/
    • TANGO
    • LIMBO
    • DANCE
    • BROADWAY
    • Other Trials
  • News/
    • Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris
    • MedTech Strategist Nov 27, 2017
    • Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial
    • Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
    • Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINC
    • Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study
    • Late-Breaking Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at VIVA 2016
    • LIMBO-ATX Trial Begins in United States
    • LIMBO-PTA Trial Begins in Germany
    • Trent Reutiman Named CEO
    • Archives
  • Contact/
Mercator MedSystems

Think outside the lumen

Peer-Reviewed Publications

Mercator MedSystems
  • Home/
  • About Us/
    • Corporate Mission
    • Officers and Directors
  • Products/
    • Bullfrog Micro-Infusion Device
    • Blowfish Transbronchial Micro-Infusion Device
  • Science and Technology/
    • Peripheral Artery Disease
    • Bronchial Carcinoma
    • Peer-Reviewed Publications
  • Clinical Trials/
    • TANGO
    • LIMBO
    • DANCE
    • BROADWAY
    • Other Trials
  • News/
    • Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris
    • MedTech Strategist Nov 27, 2017
    • Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial
    • Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
    • Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINC
    • Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study
    • Late-Breaking Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at VIVA 2016
    • LIMBO-ATX Trial Begins in United States
    • LIMBO-PTA Trial Begins in Germany
    • Trent Reutiman Named CEO
    • Archives
  • Contact/
  • Razavi MK, Donohoe D, D'Agostino RB Jr, Jaff MR, Adams G; DANCE Investigators. Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease: 12-Month Results From the DANCE Clinical Trial. JACC Cardiovasc Interv. 2018 May 28;11(10):921-931.
  • Tsukada H, Entcheva-Dimitrov P, Ernst A, Rafeq S, Keating JH, Seward KP, Yarmus L. Pharmacokinetics and safety of paclitaxel delivery into porcine airway walls by a new endobronchial drug delivery catheter. Respirology. 2018 Apr;23(4):399-405.
  • Kipshidze N, Sievert H, Wholey MH, Kipiani K, Kipiani V, Mukhuradze T, Wholey M, Stein E, Venkateswara Rao KT. First Clinical Experience With Targeted REnal Nerve Demodulation (TREND-1) Using a Neurotropic Agent for the Treatment of Sympathetic Hypertension. J Invasive Cardiology. 2017 Jan 15;ePub ahead of print:1-7.
  • Tsukada H, Seward KP, Rafeq S, Kocher O, Ernst A. Experimental Pilot Study of a Novel Endobronchial Drug Delivery Catheter. J Bronchology Interv Pulmonol. 2015 Oct;22(4):312-8. 
  • Owens CD, Gasper WJ, Walker JP, Alley HF, Conte MS, Grenon SM. Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization. J Vasc Surg. 2014 Apr;59(4):1016-24. 
  • Gasper WJ, Jimenez CA, Walker J, Conte MS, Seward K, Owens CD. Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation. Circ Cardiovasc Interv. 2013 Dec;6(6):701-9.
  • Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn FO, Strasser D, Ting AE, Sherman W. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res. 2012 Jan 20;110(2):304-11.
  • Medicetty S, Wiktor D, Lehman N, Raber A, Popovic ZB, Deans R, Ting AE, Penn MS. Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant. 2012;21(6):1109-20.
  • Karanian JW, Peregoy JA, Chiesa OA, Murray TL, Ahn C, Pritchard WF. Efficiency of drug delivery to the coronary arteries in swine is dependent on the route of administration: assessment of luminal, intimal, and adventitial coronary artery and venous delivery methods. J Vasc Interv Radiol. 2010 Oct;21(10):1555-64.

Copyright Mercator MedSystems 2019. All rights reserved.